Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANQUILITY 2
NCT05062330Phase 3Completed
- Sponsor
- Aldeyra Therapeutics
- Start
- Aug 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of reproxalap in dry eye disease (DED), sponsored by Aldeyra Therapeutics. Started Aug 2021; status: completed.
02
Drugs
reproxalap
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05062330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05062330.